Elevated circulating sclerostin correlates with advanced disease features and abnormal bone remodeling in symptomatic myeloma: reduction post-bortezomib monotherapy.
about
Role of osteocytes in multiple myeloma bone diseaseManagement of endocrine disease: Secondary osteoporosis: pathophysiology and managementInhibiting the osteocyte-specific protein sclerostin increases bone mass and fracture resistance in multiple myelomaThe effects of proteasome inhibitors on bone remodeling in multiple myeloma.The best of both worlds - managing the cancer, saving the bone.Novel therapeutic targets in myeloma bone disease.Multiple myeloma mesenchymal stromal cells: Contribution to myeloma bone disease and therapeuticsA review of osteocyte function and the emerging importance of sclerostinBiomechanical forces in the skeleton and their relevance to bone metastasis: biology and engineering considerations.unveiling skeletal fragility in patients diagnosed with MGUS: no longer a condition of undetermined significance?LIGHT/TNFSF14 increases osteoclastogenesis and decreases osteoblastogenesis in multiple myeloma-bone disease.Impaired osteoblastogenesis in a murine model of dominant osteogenesis imperfecta: a new target for osteogenesis imperfecta pharmacological therapy.Osteocytes and Skeletal PathophysiologyBidirectional Notch Signaling and Osteocyte-Derived Factors in the Bone Marrow Microenvironment Promote Tumor Cell Proliferation and Bone Destruction in Multiple MyelomaMultiple myeloma in the marrow: pathogenesis and treatments.Regulatory pathways associated with bone loss and bone marrow adiposity caused by aging, chemotherapy, glucocorticoid therapy and radiotherapy.Cellular mechanisms of multiple myeloma bone diseaseWnt and Wnt inhibitors in bone metastasis.Mechanisms of multiple myeloma bone disease.The osteocyte: an endocrine cell ... and more.Effects of proteasome inhibitors on bone cancerSerum sclerostin levels in renal cell carcinoma patients with bone metastasesClinical utility of serum sclerostin measurements.Prevention and treatment of myeloma bone disease.Signaling between tumor cells and the host bone marrow microenvironment.Management of bone disease in multiple myeloma.Myeloma and Bone Disease.Molecular mechanisms, current management and next generation therapy in myeloma bone disease.Extensive Remineralization of Large Pelvic Lytic Lesions Following Total Therapy Treatment in Patients With Multiple Myeloma.Role and mechanism of action of sclerostin in bone.Mesenchymal stem cell contact promotes CCN1 splicing and transcription in myeloma cellsHormonal and systemic regulation of sclerostin.Emerging treatment approaches for myeloma-related bone disease.Vitamin D and plasma cell dyscrasias: reviewing the significance.Regulation of Sclerostin Expression in Multiple Myeloma by Dkk-1: A Potential Therapeutic Strategy for Myeloma Bone Disease.Sclerostin induced tumor growth, bone metastasis and osteolysis in breast cancer.(18)F-fluoride-PET for dynamic in vivo monitoring of bone formation in multiple myeloma.Expression of osteoblast and osteoclast regulatory genes in the bone marrow microenvironment in multiple myeloma: only up-regulation of Wnt inhibitors SFRP3 and DKK1 is associated with lytic bone disease.Genetic deletion of Sost or pharmacological inhibition of sclerostin prevent multiple myeloma-induced bone disease without affecting tumor growth.Monoclonal antibodies for treating osteoporosis.
P2860
Q26992195-9F59447D-956B-46B9-88AF-393756CAC800Q26998249-586954FF-36CB-4022-A486-160C77BEE367Q33856318-894F6D64-5FAF-4AA4-BE18-807488776491Q33918020-0C50E207-8628-47D0-BB79-8A9BCBE647CBQ33920055-102B27D8-8959-4CB5-8257-E80F4EC662F8Q34025065-24B5FB70-A52C-499D-96BC-4781CC1B009EQ34038854-FD406A9D-B668-4090-93D2-0F83BFE7F155Q34264395-E2B35FCD-5EAA-43FA-9ABD-66D1D2F6AAD9Q34646678-284C327B-4535-4290-A4B7-439F627F31F2Q34718186-464B31D1-28CA-4F67-941A-B39077BB9185Q35149611-C7D2BACA-62C5-481C-BF78-0829BA926205Q36282399-29D9DE7F-460E-455A-A816-7B6B34B5B380Q36357606-9DF1510A-CD53-4331-9838-1A33C8F2F83AQ36642956-F7E8AA0D-78BF-438A-9308-8FB76E9E0034Q36725401-5165D9EC-306C-4C54-A76C-DB0DE0F6EDABQ36796392-06DBA1D7-EBE2-4C73-A3CB-EDE7EE621A58Q36925346-44B8FD59-A185-4001-8B60-BF21707B6639Q37056355-2A8F2A8E-C47F-44B4-9740-6A6716A5968DQ37056408-11C70E97-DFD1-4DE5-A57C-39D124461ECCQ37203605-B022CA7B-50E9-4285-AB42-FA22414C9036Q37281071-26325C15-9B7D-468E-9B9D-1E41138AAB3DQ37282121-B5D3248E-9E96-46F0-9B16-DD67840C6D1BQ37605570-3E0AA8D6-9AF6-4F29-A22B-5577DEE26DCFQ38039879-78A15C76-6D4F-49D3-8449-73BCC71BF84BQ38138849-47854B8F-7815-4707-94DF-09681BC45F0EQ38179039-6EA33032-DA38-4621-9AE3-CAE2B7EBDA10Q38598342-6F32CC79-C6A9-4278-BA68-4907C9D7B63AQ38749233-AD8CE1C4-8655-4579-A7A7-E8727B78E99AQ38752859-FEC6F7E3-6FF8-4505-B7B9-4B7BD4A98312Q38807230-41C1CFA8-839F-4BDD-BCC0-4BF5B2BF2D75Q38981228-D2CAD3BE-2FBE-4E3B-91DA-6448748AA8A0Q39037907-2DE1FB08-25A5-4E68-A723-9F44E769C109Q39090721-D8480AB7-BF4D-48D4-8657-5F389A296E96Q39304767-2CF70112-E868-4283-B341-8D3640C513CAQ40111192-A34C4219-F791-4D0D-8FC6-273CECD62DF8Q41194152-8A30EC82-5162-4E6A-A8DC-50E778B7D2E3Q41888643-5703450D-13D5-4068-A8A1-9339A033BBD8Q43965394-E88819AB-4F94-475C-93A8-D3D3552CB2B6Q47141750-1BFA39E5-4A23-4BE9-9A73-1A1065821087Q47638169-328FBF77-21A1-4379-98C6-364836020500
P2860
Elevated circulating sclerostin correlates with advanced disease features and abnormal bone remodeling in symptomatic myeloma: reduction post-bortezomib monotherapy.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年学术文章
@wuu
2011年学术文章
@zh
2011年学术文章
@zh-cn
2011年学术文章
@zh-hans
2011年学术文章
@zh-my
2011年学术文章
@zh-sg
2011年學術文章
@yue
2011年學術文章
@zh-hant
name
Elevated circulating sclerosti ...... n post-bortezomib monotherapy.
@en
Elevated circulating sclerosti ...... n post-bortezomib monotherapy.
@nl
type
label
Elevated circulating sclerosti ...... n post-bortezomib monotherapy.
@en
Elevated circulating sclerosti ...... n post-bortezomib monotherapy.
@nl
prefLabel
Elevated circulating sclerosti ...... n post-bortezomib monotherapy.
@en
Elevated circulating sclerosti ...... n post-bortezomib monotherapy.
@nl
P2093
P2860
P356
P1476
Elevated circulating sclerosti ...... n post-bortezomib monotherapy.
@en
P2093
Anastasia Pouli
Cornelia Bratengeier
Dimitrios Christoulas
Eirini Katodritou
Eurydiki Michalis
Evangelos Terpos
John Meletis
Konstantinos Zervas
Maria Gkotzamanidou
Sosana Delimpasi
P2860
P304
P356
10.1002/IJC.27342
P577
2011-12-21T00:00:00Z